Physician profile
Danielle Carrillo
NPI 1366992802
$4,706.46
in general payments reported to CMS, 2019-2025
24 companies · $1,224 in 2025
The $1,224 reported for 2025 was more than what 89% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $254 · 2022: $748 · 2023: $1,096 · 2024: $1,385 · 2025: $1,224.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,705.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,705.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $974.96 | 2021-2025 | |
| Genzyme Corporation | $644.59 | 2022-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $519.84 | 2021-2024 | Xifaxan, Plenvu, Trulance |
| Takeda Pharmaceuticals U.S.A., INC. | $395.19 | 2021-2025 | Entyvio, Eohilia |
| Janssen Biotech, INC. | $271.41 | 2021-2025 | Tremfya, Stelara, Simponi Aria |
| Pfizer INC. | $264.07 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $197.70 | 2024-2025 | Dupixent |
| Phathom Pharmaceuticals, INC. | $195.92 | 2023-2025 | Voquezna |
| Nestle Healthcare Nutrition INC. | $186.43 | 2022-2023 | |
| Ferring Pharmaceuticals INC. | $160.85 | 2022-2025 | Rebyota |
| Gilead Sciences, INC. | $145.35 | 2021-2025 | |
| Celgene Corporation | $139.78 | 2022-2024 | Zeposia |
| Intercept Pharmaceuticals, INC. | $106.16 | 2021-2023 | Ocaliva |
| Ipsen Biopharmaceuticals, INC | $82.69 | 2024-2025 | Iqirvo |
| Amgen INC. | $67.26 | 2023 | Avsola, Amjevita |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $64.22 | 2023-2025 | Omvoh |
| Impulse Dynamics (USA) INC. | $50.77 | 2023 | Optimizer |
| Organon LLC | $49.19 | 2022-2024 | Hadlima |
| Aimmune Therapeutics, INC. | $49.17 | 2024 | |
| Ardelyx, INC. | $40.28 | 2022-2023 | Ibsrela |
| Celltrion USA INC. | $37.09 | 2024-2025 | Vegzelma |
| Merck Sharp & Dohme LLC | $30.15 | 2021-2024 | Dificid |
| Teva Pharmaceuticals USA, INC. | $18.19 | 2024 | Simlandi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.20 | 2023 | Cyltezo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Danielle Carrillo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.